For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

If you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Taking a GLP-1 receptor agonist prior to bariatric surgery may not boost long-term weight loss and metabolic benefits, a ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

The news has been littered with stories these days about people losing weight using GLP-1 weight loss drugs like Ozempic. Now ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...